Mark Breidenbach
Stock Analyst at Oppenheimer
(1.12)
# 3,413
Out of 4,789 analysts
59
Total ratings
25%
Success rate
-0.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $11.88 | +152.53% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.46 | +790.41% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.58 | +975.95% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $7.02 | +1,253.28% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.52 | +1,544.74% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.91 | +997.69% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.70 | +1,614.04% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.96 | +5,305.41% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.46 | +379.45% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $0.91 | +3,404.54% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $3.33 | +350.45% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.24 | +9,577.42% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.25 | +779,900.00% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2,700 | $4.88 | +55,227.87% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $11.88
Upside: +152.53%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.46
Upside: +790.41%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.58
Upside: +975.95%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $7.02
Upside: +1,253.28%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.52
Upside: +1,544.74%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.91
Upside: +997.69%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.70
Upside: +1,614.04%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.96
Upside: +5,305.41%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.46
Upside: +379.45%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $0.91
Upside: +3,404.54%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $3.33
Upside: +350.45%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.24
Upside: +9,577.42%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.25
Upside: +779,900.00%
Dec 13, 2019
Upgrades: Outperform
Price Target: $2,700
Current: $4.88
Upside: +55,227.87%